Kim Maplestone joined 4DMT in February 2019 bringing over 15 years of experience in clinical operations in the biopharmaceutical industry. Kim’s operations and drug development experience ranges from early to late phase clinical programs, including those with multiple investigational drug combinations, rare and genetic disease indications, and large pharma-partnered programs.


Kim most recently served as Sr. Director, Head of Clinical Operations, at Aduro Biotech, a company focused on the advancement of novel immuno-oncology technologies. While at Aduro, Kim was a member of the Development Leadership Team and was responsible for clinical trial oversight and execution of 5 novel, early phase oncology programs.  Prior to Aduro, Kim oversaw clinical programs in pediatric and orphan/rare diseases at Ultragenyx Inc. and Terica Inc.

Kim holds a B.A. in Business Administration, Operations Management, from Western Washington University, in Bellingham, Washington.